** Telehealth firm Hims & Hers' shares gain 2% to $19.75 premarket
** Company says former deputy commissioner at U.S. Food and Drug Administration, Deb Autor, will join Hims & Hers' board
** Autor oversaw FDA's inspections and international operations between 2011 and 2013 and has also served as the agency's director of the Office of Compliance for the Center for Drug Evaluation and Research
** Company also appoints Janet Stevens as its global head of quality and safety, who most recently served as quality officer at Baxter's Hillrom unit
** HIMS offers compounded versions of semaglutide, the active ingredient in Novo Nordisk's popular weight-loss drug Wegovy
** As of last close, HIMS shares have more than doubled this year
(Reporting by Bhanvi Satija in Bengaluru) ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。